Related Experiment Videos
[Clinical experience with an ampicillin suppository (KS-R1) in bacterial infections in children]
Insights
Ampicillin-prolific-acid suppositories (KS-R1) demonstrated 100% effectiveness in treating pediatric bacterial infections, with no observed side effects. This antibiotic is a promising option for children
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Clinical Microbiology
Context:
- Bacterial infections are a common cause of illness in children.
- Effective and safe antibiotic treatments are crucial for pediatric care.
- The development of novel drug delivery systems, like suppositories, can improve treatment adherence and efficacy.
Purpose:
- To evaluate the clinical effectiveness and safety of ABPC suppository (KS-R1) in treating bacterial infections in children.
- To assess the efficacy of KS-R1 against specific bacterial strains causing common pediatric infections.
Summary:
- A clinical study was conducted on 14 pediatric patients with bacterial infections including acute tonsillitis, pneumonia, otitis media, and urinary tract infections (UTIs).
- Patients received KS-R1 suppositories at an average dose of 38.5 mg/kg/day for an average of 4 days.
- The treatment achieved a 100% overall efficacy rate, with 8 out of 8 bacterial strains eradicated. No clinical side effects or laboratory abnormalities were reported.
Impact:
- KS-R1 suppository presents a safe and highly effective therapeutic option for pediatric bacterial infections.
- The study supports the utility of ABPC suppositories as a valuable addition to the pediatric infectious disease treatment armamentarium.
- Further research may explore broader applications and long-term outcomes of KS-R1 in pediatric populations.
Abstract:
In order to evaluate effectiveness of ABPC suppository (KS-R1) in the treatment of bacterial infections of children, the clinical studies were carried out. KS-R1 was given in rectum to 14 patients in doses of 24.2 approximately 65.8 mg/kg (average 38.5 mg/kg) in 3 approximately 4 divided doses for 3 approximately 8 days (average 4.0 days); 6 with acute tonsillitis, 3 with pneumonia, 1 with otitis media, 4 with UTI. The overall efficacy rate was 100%. Bacterial efficacy was good, i.e. 8 of the 8 strains disappeared. Any clinical side effects and laboratory abnormalities were not observed during treatment. The above results suggested that KS-R1 is a useful antibiotics for pediatric bacterial infections.